Page last updated: 2024-11-05

troglitazone and Intestinal Diseases

troglitazone has been researched along with Intestinal Diseases in 1 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Intestinal Diseases: Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Li, E1
Li, C1
Horn, N1
Ajuwon, KM1

Other Studies

1 other study available for troglitazone and Intestinal Diseases

ArticleYear
PPARĪ³ activation inhibits endocytosis of claudin-4 and protects against deoxynivalenol-induced intestinal barrier dysfunction in IPEC-J2 cells and weaned piglets.
    Toxicology letters, 2023, Feb-15, Volume: 375

    Topics: Animals; Claudin-3; Claudin-4; Endocytosis; Epithelial Cells; Intestinal Diseases; Intestinal Mucosa

2023